Badanie skuteczności zanubrutinibu i obinutuzumabu u pacjentów z przewlekłą białaczką limfocytową lub chłoniakiem limfocytowym małych limfocytów, którzy nie byli wcześniej leczeni

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are types of blood cancers that affect certain white blood cells. These diseases can cause symptoms like fatigue, swollen lymph nodes, and frequent infections. The study focuses on patients who have not yet received treatment for these conditions. The purpose is to evaluate the effectiveness and safety of a combination of two medications: zanubrutinib and obinutuzumab. Zanubrutinib is taken as a capsule, while obinutuzumab is given through an infusion into a vein.

The study aims to compare how well these medications work together in achieving complete remission, which means the absence of detectable cancer cells. Participants will receive the combination of zanubrutinib and obinutuzumab according to different schedules to see which is more effective. The study will also monitor the safety of the treatment, looking at any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, participants will have regular check-ups to assess their response to the treatment and to ensure their well-being. The study will help determine the best way to use these medications for treating CLL and SLL, potentially improving outcomes for patients with these conditions.